201410-53-9

Basic information

• Product Name: R 115866
• Synonyms: R 115866;RaMbazole;N-[4-[2-Ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]-2-benzothiazolamine;N-(4-(2-Ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine)
• CAS NO: 201410-53-9
• Molecular Formula: C21H23N5S
• Molecular Weight: 377.50582
• Mol File: 201410-53-9.mol

Chemical Properties

• Boiling Point: 561.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• Solubility: Soluble in DMSO
• PKA: 2.70±0.10(Predicted)
• CAS DataBase Reference: R 115866(CAS DataBase Reference)
• NIST Chemistry Reference: R 115866(201410-53-9)
• EPA Substance Registry System: R 115866(201410-53-9)

Safety Data

• Hazardous Substances Data: 201410-53-9(Hazardous Substances Data)

Usage

Uses

Used in Dermatology:
R 115866 is used as a therapeutic agent for treating dermatological diseases such as psoriasis and acne. Its mechanism of action involves blocking the metabolism of retinoic acid, which helps in reducing inflammation and promoting skin cell turnover.
Used in Pharmaceutical Industry:
R 115866 is used as a key ingredient in the development of pharmaceutical formulations for dermatological treatments. Its ability to modulate retinoic acid metabolism makes it a promising candidate for the management of various skin conditions.

Biological Activity

talarozole is a selective inhibitor of cytochrome p450 with an ic50 at 4 nm [1].cytochrome p450 is concerned with oxidative metabolism of many organic chemicals of diverse structure,both in exogenous and endogenous environment. cytochrome p450 are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act.talarozole is a potent and selective inhibitor of cytochrome p450 26-mediated breakdown of endogenous all-trans-retinoic acid for the treatment of psoriasis and acne. talarozole treatment increased the mrna expression of crabp2, krt4, cyp26a1 and cyp26b1 dose, meanwhile, compared with vehicle-treated skin, decreased the expression of krt2 and il-1α. there was no mrna change in retinol-metabolizing enzymes. no induction of epidermal thickness or overt skin inflammation in talarozole-treated skin. immunofluorescence analysis substantiated an upregulation of krt4 protein, however, there were no upregulation of cyp26b1 and cyp26a1 expression was found.[1, 2]there were 0.1% of the dose found in the skin itself after 12-24 h. the results of distribution of talarozole within the skin show that 80% was located in the epidermis, meanwhile, the remaining 20% was detected in the dermis. [3]

references

[1] pavez loriè e, cools m, borgers m, topical treatment with cyp26 inhibitor talarozole (r115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. the british journal of dermatology,2009,160(1):26-36. [2] geria an, scheinfeld ns. talarozole, a selective inhibitor of p450-mediated all-trans retinoic acid for the treatment of psoriasis and acne. current opinion in investigational drugs,2008 ,9(11):1228-1237.[3] baert b, de spiegeleer b. local skin pharmacokinetics of talarozole, a new retinoic acid metabolism-blocking agent. skin pharmacol physiol,2011,24(3):151-159

Upstream product

• 137-07-5 2-amino-benzenethiol 

Relevant articles and documents

N-[4-(Heteroarylmethyl)phenyl]-heteroarylamines

PCT No. PCT/EP97/03248 Sec. 371 Date Apr. 29, 1999 Sec. 102(e) Date Apr. 29, 1999 PCT Filed Jun. 19, 1997 PCT Pub. No. WO97/49704 PCT Pub. Date Dec. 31, 1997The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically ac